JP2005515214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515214A5 JP2005515214A5 JP2003556020A JP2003556020A JP2005515214A5 JP 2005515214 A5 JP2005515214 A5 JP 2005515214A5 JP 2003556020 A JP2003556020 A JP 2003556020A JP 2003556020 A JP2003556020 A JP 2003556020A JP 2005515214 A5 JP2005515214 A5 JP 2005515214A5
- Authority
- JP
- Japan
- Prior art keywords
- tfpi
- pharmaceutical composition
- analog
- ala
- glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 64
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 57
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 57
- 239000000203 mixture Substances 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 238000001802 infusion Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 208000038016 acute inflammation Diseases 0.000 claims 2
- 230000006022 acute inflammation Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000004074 complement inhibitor Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229940124073 Complement inhibitor Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- -1 antibodies Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003589 arginine hydrochloride Drugs 0.000 claims 1
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 claims 1
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32880601P | 2001-10-15 | 2001-10-15 | |
| PCT/US2002/032625 WO2003055442A2 (en) | 2001-10-15 | 2002-10-15 | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005271191A Division JP2006008704A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515214A JP2005515214A (ja) | 2005-05-26 |
| JP2005515214A5 true JP2005515214A5 (https=) | 2006-01-05 |
Family
ID=23282520
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535710A Withdrawn JP2005506345A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2003556020A Withdrawn JP2005515214A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2005271219A Pending JP2006008706A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2005271191A Withdrawn JP2006008704A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2009235793A Withdrawn JP2010006839A (ja) | 2001-10-15 | 2009-10-09 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535710A Withdrawn JP2005506345A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005271219A Pending JP2006008706A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2005271191A Withdrawn JP2006008704A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2009235793A Withdrawn JP2010006839A (ja) | 2001-10-15 | 2009-10-09 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7674769B2 (https=) |
| EP (2) | EP1446140A4 (https=) |
| JP (5) | JP2005506345A (https=) |
| KR (2) | KR20050036867A (https=) |
| CN (2) | CN1604790A (https=) |
| AU (2) | AU2002340183B2 (https=) |
| BR (2) | BR0213293A (https=) |
| CA (2) | CA2463738A1 (https=) |
| EA (2) | EA200400549A1 (https=) |
| HU (2) | HUP0500472A2 (https=) |
| IL (2) | IL161408A0 (https=) |
| IS (2) | IS7223A (https=) |
| MX (2) | MXPA04003547A (https=) |
| NO (2) | NO20041996D0 (https=) |
| PL (2) | PL374506A1 (https=) |
| WO (2) | WO2003055442A2 (https=) |
| ZA (2) | ZA200403601B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1446140A4 (en) | 2001-10-15 | 2007-03-07 | Novartis Vaccines & Diagnostic | TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR) |
| CA2512680A1 (en) * | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| WO2005019265A1 (en) | 2003-08-13 | 2005-03-03 | Chiron Corporation | Improved method of purifying tfpi and tfpi analogs |
| SG150552A1 (en) * | 2004-03-17 | 2009-03-30 | Chiron Corp | Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| CA2605057A1 (en) * | 2005-04-15 | 2006-10-26 | Abla Creasey | Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi) |
| WO2006122139A2 (en) * | 2005-05-06 | 2006-11-16 | Novartis Ag | Use of tfpi to treat severe bacterial infections |
| CN102961746B (zh) | 2005-05-16 | 2016-06-15 | 艾伯维生物技术有限公司 | TNFα抑制剂治疗腐蚀性多关节炎的用途 |
| ZA200800251B (en) * | 2005-06-24 | 2009-04-29 | Drugrecure Aps | Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track |
| WO2007014199A2 (en) * | 2005-07-22 | 2007-02-01 | Novartis Ag | Tfpi fragments as anti-microbial agents |
| EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| WO2009014633A1 (en) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| WO2009129164A1 (en) * | 2008-04-15 | 2009-10-22 | Novartis Ag | Pharmaceutical combinations of tfpi-fragments and an antibiotic |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| US20120148542A1 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
| JP2014520873A (ja) | 2011-07-18 | 2014-08-25 | ザ ユニバーシティ オブ メルボルン | ｃ−Ｆｍｓアンタゴニストの使用 |
| BR112014011488B1 (pt) * | 2011-11-15 | 2022-07-05 | Asahi Kasei Pharma Corporation | Medicamento para tratamento terapêutico e/ou melhora de sépsis |
| SG11201507871XA (en) | 2013-04-12 | 2015-10-29 | Morphosys Ag | Antibodies targeting m-csf |
| US11504071B2 (en) | 2018-04-10 | 2022-11-22 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| US11908581B2 (en) | 2018-04-10 | 2024-02-20 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| BR112021007460A2 (pt) | 2018-10-22 | 2021-11-03 | Asahi Kasei Pharma Corp | Medicamento para tratamento terapêutico e/ou melhora de um paciente com sepse |
| WO2023142096A1 (en) * | 2022-01-30 | 2023-08-03 | Westlake University | Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4603106A (en) | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3219248A1 (de) | 1982-05-21 | 1983-11-24 | Solco Basel AG, Birsfelden | Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4620948A (en) | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4711845A (en) | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| WO1985004899A1 (en) | 1984-04-19 | 1985-11-07 | Agracetus | Methods and vectors for transformation of plant cells |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4847201A (en) | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5110730A (en) | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
| US4966852A (en) | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
| IL87171A (en) | 1987-11-23 | 1995-08-31 | Monsanto Co | cDNA of human tissue factor inhibitor |
| US5219994A (en) | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| DK412389D0 (da) | 1989-01-19 | 1989-01-19 | Novo Nordisk As | Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning |
| DK408089D0 (da) | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Proteiner |
| DK148890D0 (da) | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
| DE69118056T2 (de) | 1990-08-27 | 1996-10-24 | Monsanto Co | Anticoagulatorische Zusammensetzung aus LACI und sulfatierten Polysacchariden |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
| US5212091A (en) * | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
| USRE36476E (en) | 1992-03-18 | 1999-12-28 | Washington University | Method of inhibiting microvascular thrombosis |
| US5276015A (en) | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
| PT643585E (pt) * | 1992-06-01 | 2000-05-31 | Chiron Corp | Utilizacao de inibidor da coagulacao associado a lipoproteinas (laci) para a preparacao de um medicamento para o tratamento de inflamacao aguda ou cronica |
| US6063764A (en) | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| AU4408493A (en) | 1992-06-11 | 1994-01-04 | Washington University | Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders |
| US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| JP3571378B2 (ja) * | 1994-09-30 | 2004-09-29 | 扶桑薬品工業株式会社 | 感染症診断用プローブ |
| JP3761914B2 (ja) * | 1994-11-17 | 2006-03-29 | 財団法人化学及血清療法研究所 | アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤 |
| US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
| US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| US5885781A (en) | 1995-06-07 | 1999-03-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
| DE69635051T2 (de) | 1995-06-07 | 2006-06-14 | Chiron Corp | Methode zur lösung, reinigung und rückfaltung von protein |
| US5888968A (en) | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5902582A (en) | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
| US5772629A (en) * | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
| US5736364A (en) | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| ATE254472T1 (de) | 1996-03-25 | 2003-12-15 | Chemo Sero Therapeut Res Inst | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält |
| US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
| CA2279345A1 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
| US5981471A (en) | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| UA55448C2 (uk) | 1997-04-28 | 2003-04-15 | Елі Ліллі Енд Компані | Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить |
| IL121191A0 (en) | 1997-06-29 | 1997-11-20 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| WO2000023101A1 (en) | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
| WO2000030677A1 (en) | 1998-11-20 | 2000-06-02 | Eli Lilly And Company | Method of treating viral hemorrhagic fever |
| WO2000077254A1 (en) * | 1999-06-11 | 2000-12-21 | The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services | Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection |
| AU5062100A (en) | 1999-06-14 | 2001-01-02 | Novo Nordisk A/S | Fviia/tf activity inhibiting compounds |
| US6294648B1 (en) | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
| US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
| DE60031999T2 (de) | 1999-10-04 | 2007-06-06 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen |
| WO2001049315A1 (en) | 2000-01-06 | 2001-07-12 | Eli Lilly And Company | Combination therapy for the treatment of inflammatory and respiratory diseases |
| CA2400187A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| KR20020081330A (ko) | 2000-02-16 | 2002-10-26 | 노오쓰웨스턴 유니버시티 | 폴리펩토이드 폐 계면활성제 |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| WO2002102325A2 (en) | 2001-02-28 | 2002-12-27 | Griffin John H | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c |
| EP1383885A4 (en) | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF |
| DE10132307A1 (de) | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| EP1446140A4 (en) | 2001-10-15 | 2007-03-07 | Novartis Vaccines & Diagnostic | TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR) |
| US20020198138A1 (en) | 2002-06-07 | 2002-12-26 | Macias William Louis | Combination therapy for the treatment of inflammatory and respiratory diseases |
-
2002
- 2002-10-15 EP EP02778529A patent/EP1446140A4/en not_active Withdrawn
- 2002-10-15 HU HU0500472A patent/HUP0500472A2/hu unknown
- 2002-10-15 KR KR1020047005618A patent/KR20050036867A/ko not_active Withdrawn
- 2002-10-15 MX MXPA04003547A patent/MXPA04003547A/es unknown
- 2002-10-15 WO PCT/US2002/032625 patent/WO2003055442A2/en not_active Ceased
- 2002-10-15 BR BR0213293-1A patent/BR0213293A/pt not_active Application Discontinuation
- 2002-10-15 IL IL16140802A patent/IL161408A0/xx unknown
- 2002-10-15 EP EP02803284A patent/EP1446138A4/en not_active Withdrawn
- 2002-10-15 JP JP2003535710A patent/JP2005506345A/ja not_active Withdrawn
- 2002-10-15 AU AU2002340183A patent/AU2002340183B2/en not_active Ceased
- 2002-10-15 KR KR10-2004-7005632A patent/KR20040040489A/ko not_active Withdrawn
- 2002-10-15 BR BRPI0213292-3A patent/BR0213292A/pt unknown
- 2002-10-15 IL IL16140702A patent/IL161407A0/xx unknown
- 2002-10-15 PL PL02374506A patent/PL374506A1/xx not_active Application Discontinuation
- 2002-10-15 CA CA002463738A patent/CA2463738A1/en not_active Abandoned
- 2002-10-15 EA EA200400549A patent/EA200400549A1/ru unknown
- 2002-10-15 CA CA002463655A patent/CA2463655A1/en not_active Abandoned
- 2002-10-15 CN CNA028249003A patent/CN1604790A/zh active Pending
- 2002-10-15 HU HU0501111A patent/HUP0501111A2/hu unknown
- 2002-10-15 EA EA200400548A patent/EA200400548A1/ru unknown
- 2002-10-15 US US10/270,478 patent/US7674769B2/en not_active Expired - Fee Related
- 2002-10-15 WO PCT/US2002/032624 patent/WO2003032904A2/en not_active Ceased
- 2002-10-15 CN CNA028250648A patent/CN1604787A/zh active Pending
- 2002-10-15 AU AU2002365131A patent/AU2002365131B2/en not_active Ceased
- 2002-10-15 JP JP2003556020A patent/JP2005515214A/ja not_active Withdrawn
- 2002-10-15 PL PL02372138A patent/PL372138A1/xx not_active Application Discontinuation
-
2003
- 2003-02-04 US US10/270,479 patent/US20030139340A1/en not_active Abandoned
-
2004
- 2004-04-15 IS IS7223A patent/IS7223A/is unknown
- 2004-04-15 IS IS7224A patent/IS7224A/is unknown
- 2004-04-15 MX MXPA04003548A patent/MXPA04003548A/es not_active Application Discontinuation
- 2004-05-11 ZA ZA200403601A patent/ZA200403601B/en unknown
- 2004-05-13 ZA ZA200403690A patent/ZA200403690B/xx unknown
- 2004-05-14 NO NO20041996A patent/NO20041996D0/no not_active Application Discontinuation
- 2004-05-14 NO NO20041997A patent/NO20041997D0/no not_active Application Discontinuation
-
2005
- 2005-09-16 JP JP2005271219A patent/JP2006008706A/ja active Pending
- 2005-09-16 JP JP2005271191A patent/JP2006008704A/ja not_active Withdrawn
-
2009
- 2009-10-09 JP JP2009235793A patent/JP2010006839A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005515214A5 (https=) | ||
| von Stebut et al. | IL-17A in psoriasis and beyond: cardiovascular and metabolic implications | |
| JP2005506345A5 (https=) | ||
| US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
| JPH09510434A (ja) | 重症の急性膵炎を改善するインターロイキン−１レセプター拮抗薬 | |
| IL112427A (en) | Production of pharmaceutical compositions comprising anti-tnf antibodies | |
| JP2010006839A (ja) | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 | |
| US20060171948A1 (en) | Methods of using IL-1 antagonists to reduce C-reactive protein | |
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| CN106535895A (zh) | 丁型肝炎病毒感染的治疗 | |
| JP2021514354A5 (https=) | ||
| Mittelman et al. | A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion | |
| JP2008540460A (ja) | 重症細菌感染を処置するためのｔｆｐｉの使用 | |
| CN1946734B (zh) | 系统性治疗关节炎的组合物和方法 | |
| US20040072805A1 (en) | Use of tumor necrosis factor inhibitors to treat cardiovascular disease | |
| AU2022256212A1 (en) | Glutarimide derivative for overcoming resistance to steriods | |
| TW202128212A (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| JP2002371006A (ja) | 肺線維症予防および／または進行防止剤 | |
| US20050043230A1 (en) | Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases | |
| AU2002362753B9 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
| EP4065115A1 (en) | A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis | |
| JPWO2019165140A5 (https=) | ||
| RU2006136267A (ru) | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) | |
| AU2002362753A1 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
| RU2007142192A (ru) | Лечение тяжелой внебольничной пневмонии с помощью введения ингибитора пути тканевого фактора (tfpi) |